Company intelligence / Profile preview

Ocw holding

Ownership: Private
Development stage: Other

Overview

Oculis has three main clinical programs targeting ophthalmic diseases. Its lead candidate, a topical dexamethasone formulation called OCS‑01, is in Phase 3 trials for diabetic macular edema. The second program, a biologic named OCS‑02, targets dry eye disease and is currently in Phase b trials. The third asset, a neuroprotective agent called OCS‑05, addresses neurological damage from glaucoma and other retinal conditions and has reached early-stage clinical development. No pivotal readouts or commercial approvals have been reported as of June 2025.

Therapeutic areas: Ophthalmology
Modalities: Small moleculeBiologic
Industry: Biotech

Beyond the preview

Go deeper on Ocw holding.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ocw holding.

Explore the full profile